FDA Approves Tepylute (thiotepa) Ready-to-Dilute Injectable Formulation to Treat Breast Cancer and Ovarian Cancer

Shorla Oncology's Tepylute, a liquid form of thiotepa, simplifies oncology drug use, reducing medical personnel exposure to hazardous drugs. It's Shorla's third FDA-approved drug and their first in-house developed NDA, aiming to address unmet needs in cancer treatment.